HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Manufacturers Consider Design Changes For OTC Propylhexedrine Nasal Decongestant Inhalers

Executive Summary

"Manufacturers are already working on possible solutions to address the concerns and will work with the Agency to implement any appropriate measures,” says CHPA senior VP  Barbara Kochanowski.

You may also be interested in...



Propylhexedrine Abuse Prompts US FDA To Suggest OTC Nasal Inhaler Modifications, Smaller Size

FDA published warning against abuse of propylhexedrine, but study published in October 2020 questioned why sales of products with the ingredient aren’t limited like sales of pseudoephedrine-containing OTCs under a federal law.

Pseudoephedrine Tide Turns: Nonprescription Sales Return In Mississippi, Oregon Mulls Change

Mississippi repeals prescription requirement for all pseudoephedrine- and ephedrine-containing drugs while also requiring retailer participation in industry-funded technology for tracking drug sales. Oregon, the only other state with PSE Rx law, is considering repealing it.

HBW Legislative News: Another Federal CR, Michigan On DXM List, Senators Say Supplements Are 'Medical Expenses'

Federal agencies at FY 2019 funding for another month; Michigan imposes age restriction on OTC DXM sales; and senators urge IRS to make supplements 'medical expenses'.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS151162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel